Guo Rong-ping | Liver Surgery | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Guo Rong-ping

Title: Deputy Director and Professor of Liver Surgery Department

Email: guorp@sysucc.org.cn

Phone:

Profile

Dr. Rong-ping Guo is professor, PhD supervisor and vice-director of Department of Hepatobiliary Tumor of Sun Yat-sen University Cancer Center. Dr. Guo obtained his Bachelor in Medicine (equivalent to MD in the US) and Master at Sun Yat-sen University of Medical Sciences, P. R. China in 1988 and 1994, respectively. From 1988,Dr.Guo was engage in the clinical and theoretical research of hepatobiliary tumor. Dr.Guo worked as visiting bachelor in Queen Mary Hospital of Hong Kong University and Prince of Wales Hospital of Chinese University of Hong Kong from Apr 2003 to Dec 2003. After then he worked as visiting bachelor in Organ Transplantation Center of University of Pittsburgh from Apr 2004 to Sep 2004. Dr.Guo now lead a research team in Department of Hepatobiliary Tumor and specialize in diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation and liver transplantation. The work of Dr.Guo and his team has got support by different fund including National natural science foundation of China and has published more than 10 SCI papers.

Interests

Diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation ,target therapy and liver transplantation, especially the multidisciplinary treatments for advanced HCC. His basic research fields including tumorigenesis, angiogenesis and metastasis of HCC

Education

1982-1988 Faculty of clinical medicine of Sun Yat-sen University of Medical Sciences, Bachelor

1991-1994 Faculty of Clinical Oncology of Sun Yat-sen University of Medical Sciences, Master

Publications

1.Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP.Br J Cancer. 2014 Feb 4;110(3):733-40.

2. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection.Li SH, Guo ZX, Xiao CZ, Wei W, Shi M, Chen ZY, Cai MY, Zheng L, Guo RP. Asian Pac J Cancer Prev. 2013;14(8):4759-63.

3. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors.Li SH, Wei W, Guo RP, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Med Oncol. 2013 Dec;30(4):696.

4. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP.J Transl Med. 2012 Dec 10;10:245

5. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ.J Natl Cancer Inst. 2013 Jan 2;105(1):59-68.

6. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus.Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Cancer. 2012 Oct 1;118(19):4725-36.

7. Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection.Zhong C, Wei W, Su XK, Li HD, Xu FB, Guo RP. Hepatogastroenterology. 2012 Jan-Feb;59(113):93-7.

8. Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection.Chen ZY, Wei W, Guo ZX, Lin JR, Shi M, Guo RP. J Gastroenterol Hepatol. 2011 May;26(5):866-74.

9. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M. Radiology. 2011 Apr;259(1):286-95.

10. ransarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Ann Surg Oncol. 2011 Feb;18(2):413-20

11. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45.

12. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Ann Surg. 2007 Jan;245(1):36-43.

Updated by International Office, Sun Yat-sen University Cancer Center

Our Experts